Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men.

Trial Profile

Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Testosterone undecanoate (Primary) ; Testosterone
  • Indications Hypogonadism
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2012 Primary endpoint 'Testosterone-levels' has been met according to a Clarus Therapeutics media release.
    • 01 May 2012 Status changed from completed to active, no longer recruiting, according to a ClarusTherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top